SGLT2 inhibitors in clinical use in Europe are dapagliflozin, canagliflozin, empagliflozin and ertugliflozin while sotagliflozin, the only dual SGLT1/2 inhibitor, is approved only for type 1 diabetes (T1D). Here, SLC5A1 is linked to type 1 diabetes mellitus.